Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immune Checkpoint Inhibitors
96%
Checkpoint Inhibitor Pneumonitis
96%
Vancomycin-resistant Enterococcus Faecium (VREfm)
59%
Chest Imaging
53%
Independent Risk Factors
51%
Immune Checkpoint Therapy
43%
Risk Factors
38%
Pneumonitis
35%
Pulmonary Function Abnormalities
29%
Methicillin-resistant Staphylococcus Aureus
29%
Co-colonization
29%
Trastuzumab Deruxtecan (T-DXd)
29%
Imaging Mechanism
29%
Acute Respiratory Distress Syndrome
29%
Vancomycin-resistant Staphylococcus Aureus
29%
Case-case
22%
Asthma
22%
Retrospective Cohort Study
21%
Immune-related Adverse Events (IrAEs)
20%
Hospitalization
20%
Cancer Progression
19%
Non-immune
19%
Ohio State University
18%
Treatment Course
17%
Lung Cancer
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Columbus
15%
Non-associated
15%
Cancer-specific Survival
14%
Sarcoid-like
14%
Cancer Immunology
14%
Treatment Impact
14%
Linezolid-resistant
14%
Critically Ill Patients
14%
Single Center
14%
Compensatory Response
14%
O3 Exposure
14%
Epidemiology
14%
Reduced Susceptibility
14%
Allergic Asthma
14%
Daptomycin
14%
Steroid-refractory
14%
Treatment Options
14%
Steroid Responsive
14%
Risk Treatment
14%
Bronchoalveolar Lavage
14%
Cytokine Profile
14%
Reactive Airway Disease
14%
Transcriptome Analysis
14%
Evaluating Risks
14%
Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Chest Imaging
59%
Malignant Neoplasm
32%
Lung Function
29%
Acute Respiratory Distress Syndrome
29%
Vancomycin Resistant Enterococcus
29%
Vancomycin Resistant Staphylococcus Aureus
29%
Cancer Growth
25%
Steroids
18%
Retrospective Cohort Study
18%
Immunotherapy
15%
Case-Control Study
15%
Cancer Immunology
14%
Division
14%
Cancer Survival
14%
Lung Cancer
14%
Sarcoidosis
14%
Cytokine
14%
Lung Lavage
14%
Eosinophilic
14%
Respiratory Disease
14%
Interstitial Lung Disease
14%
Iron Homeostasis
14%
Trastuzumab Deruxtecan
14%
Metastatic Breast Cancer
14%
COVID-19
14%
Gene Expression Profiling
14%
Tocilizumab
14%
Linezolid
14%
Erythrocyte
14%
Methicillin Resistant Staphylococcus Aureus
14%
Co-Colonization
14%
Enterococcus faecalis
14%
Interleukin 6
11%
Bronchoalveolar Lavage Fluid
11%
Abemaciclib
11%
Sleep Medicine
7%
Medical Oncology
7%
Intensive Care Medicine
7%
Internal Medicine
7%
Silo-Filler's Disease
7%
Bronchoscopy
7%
Biological Marker
7%
Lung Infection
7%
Aves
7%
Lung Function Test
6%
Oncologist
5%
Autoimmunity
5%
Hazard Ratio
5%
Immunology and Microbiology
Immune Checkpoint Inhibitor
97%
Pneumonitis
67%
Lung
38%
Steroid
33%
Infectious Disease
22%
Infection
22%
Asthma
21%
Pretreatment
18%
Overall Survival
18%
Lung Function
17%
Morbidity
16%
Vancomycin-Resistant Enterococcus
14%
Immunotherapy
14%
Iron Homeostasis
14%
Systemic Inflammation
14%
Trastuzumab Emtansine
14%
COVID-19
14%
Susceptibility
14%
Allergic Asthma
14%
Gene Expression Assay
14%
Trastuzumab Deruxtecan
14%
Reactive Airway Disease
14%
Sarcoidosis
14%
Tocilizumab
14%
Erythrocyte
14%
Airway
14%
Cytokine
14%
Asthma Exacerbation
14%
Epidemiology
14%
Cohort Effect
14%
Pembrolizumab
12%
Allergic Inflammation
9%
Inflammatory Cell
9%
Mouse Model
9%
Inflammation
8%